Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 2326 to 2340 of 2854 results for process

  1. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued Reference number: GID-TAG382

    Technology appraisal guidance
    Discontinued

  2. Nitazoxanide for treating the common cold in people 12 years and over [ID4049]

    Discontinued Reference number: GID-TA11128

    Technology appraisal guidance
    Discontinued

  3. Nivolumab for treating recurrent glioblastoma [ID998]

    Discontinued Reference number: GID-TA10126

    Technology appraisal guidance
    Discontinued

  4. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    Discontinued Reference number: GID-TA11421

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]

    Discontinued Reference number: GID-TA11020

    Technology appraisal guidance
    Discontinued

  6. Botulinum toxin type A for preventing episodic migraine [ID6450]

    In development Reference number: GID-TA11505 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]

    In development Reference number: GID-TA11606 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]

    In development Reference number: GID-TA11670 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Tanezumab for treating pain caused by bone metastases [ID3784]

    Discontinued Reference number: GID-TA10922

    Technology appraisal guidance
    Discontinued

  10. Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]

    Discontinued Reference number: GID-TA11647

    Technology appraisal guidance
    Discontinued

  11. Diabetic retinopathy - ruboxistaurin [ID382]

    Discontinued Reference number: GID-TAG386

    Technology appraisal guidance
    Discontinued

  12. Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]

    Discontinued Reference number: GID-TA11033

    Technology appraisal guidance
    Discontinued

  13. Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]

    Discontinued Reference number: GID-TA11034

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]

    Discontinued Reference number: GID-TA10766

    Technology appraisal guidance
    Discontinued

  15. Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]

    Discontinued Reference number: GID-TA10616

    Technology appraisal guidance
    Discontinued